Syncom Formulations (India) Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹115.14 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 5.41 per cent from ₹121.72 crore. This corresponds to a year-on-year *(YoY) decline of 9.72 per cent.
Operating Profit
Operating Profit stands at ₹21.21 crore, reflecting a quarter-on-quarter *(QoQ) increase of 15.27 per cent from ₹18.40 crore. This corresponds to a year-on-year *(YoY) growth of 43.99 per cent.
PBDT
PBDT stands at ₹26.45 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.08 per cent from ₹23.39 crore. This corresponds to a year-on-year *(YoY) growth of 42.43 per cent.
Profit Before Tax
Profit Before Tax stands at ₹25.09 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.84 per cent from ₹22.04 crore. This corresponds to a year-on-year *(YoY) growth of 45.37 per cent.
Net Profit
Net Profit stands at ₹18.91 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.92 per cent from ₹16.60 crore. This represents a 45.46 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Syncom Formulations (India) Ltd Earnings
- YOY
- QOQ
Syncom Formulations (India) Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Syncom Formulations (India) Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Syncom Formulations (India) Ltd Financial Reports
Syncom Formulations (India) Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Syncom Formul. | -1.23% | -5.21% | 0.00% | 0.22% | -16.67% | -27.89% |
| Shukra Pharma. | -2.61% | -1.47% | -10.03% | -20.28% | -27.70% | 114.19% |
| Fredun Pharma | -1.19% | -6.13% | 14.45% | 36.08% | 22.29% | 234.15% |
| Lincoln Pharma. | -2.83% | -7.95% | 4.84% | 1.57% | 21.34% | 6.65% |
| Venus Remedies | -3.04% | -6.42% | -10.46% | 15.58% | 64.37% | 170.45% |
| Ind-Swift Labs. | -0.74% | -3.25% | 1.40% | -5.70% | 38.24% | 86.02% |
| Bajaj Healthcare | -3.01% | -6.47% | -14.65% | -20.50% | -34.66% | -49.93% |
Company Info
Company Information
Chairman & Exec. Director : Kedarmal Bankda
ED / MD / Promoter : Vijay Bankda
Independent Non Exe. Director : Ruchi Jindal
Independent Non Exe. Director : Ritesh Kumar Lunkad
Independent Non Exe. Director : Ankit Jain
Chairman / Executive Director / WTD : ANKIT KEDARMAL BANKDA
Company Sec. & Compli. Officer : Vaishali Agrawal